Shares of Crawford United Corporation (CRAWA) have gained 10.6% since the company reported its earnings for the quarter ended Sept. 30, 2025. This compares to the S&P 500 Index’s 1.8% loss over the same time frame. Over the past month, the stock gained 9.1% compared with the S&P 500’s 0.2% growth.CRAWA’s Earnings SnapshotCrawford United posted a robust third-quarter 2025 performance, marking new record highs in sales, net income and earnings per share. Quarterly sales reached $47.2 million, up 28.4% from $3 ...

Shares of SandRidge Energy, Inc. (SD) have rallied 7.8% since reporting third-quarter 2025 results, outpacing the S&P 500 index’s 0.5% rise. Over the past month, the stock has gained 6.3% compared with the S&P 500’s 1.3% growth, reflecting investor confidence following another quarter of solid operational execution and continued capital discipline.The company reported third-quarter 2025 earnings per share of 42 cents, up from 19 cents in the year-ago period. Revenues climbed 32% year over year to $39.8 mill ...

Hundreds of smartphone promotions across US carriers in October 2025 illustrate an intensifying battle for subscribers. During the month, telcos, OEMs and retailers launched 623 promotions. Across 12 promo types, trade-in credits and upgrade deals were the most prevalent tactics, underscoring the industry’s reliance on device subsidies to entice customers. Verizon, T-Mobile, and AT&T ran most of these offers, far outpacing cable MVNOs Spectrum Mobile and Xfinity Mobile. Samsung and Apple devices dominate ...

Shares of Doximity (DOCS) traded ~14% lower on Friday despite reporting better-than-expected Q2 FY26 financials after the digital medical platform flagged concerns over healthcare-policy-related uncertainty impacting its clients' annual budgets. On Thursday, after the market close, Doximity (DOCS), a ...

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives. Price charts only tell part of the story. Our team at StockStory evaluates each company's underlying fundamentals to separate temporary setbacks from structural declines. That said, here is one stock where the poor sentiment is creating a buying opportunity and two where the outlook is warranted. T ...

Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds. While market timing can be an extremely profitable strategy, it has burned many investors and requires rigorous analysis - something we specialize in at StockStory. That said, here are three stocks where the skepticism is well-placed and some better opportunities to consider. Semrush (SEMR) One-Month Return: -4.8% Bor ...

Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap? While market timing can be an extremely profitable strategy, it has burned many investors and requires rigorous analysis - something we specialize in at StockStory. That said, here are three stocks poised to prove the bears wrong. Colgate-Palmolive (CL) One-Month Return: -0.4% Formed after the 1928 co ...

Core Insights - Doximity, Inc. reported adjusted earnings per share (EPS) of 45 cents for Q2 fiscal 2026, a 50% increase year over year, exceeding the Zacks Consensus Estimate by 18.4% [1][8] - The company's revenues reached $168.5 million in Q2, reflecting a year-over-year growth of 23.2% and surpassing the Zacks Consensus Estimate by 6.8% [2][8] Revenue Breakdown - Subscription revenues amounted to $159.5 million, up 23% year over year, driven by increased spending from existing customers and a net revenue retention rate of 118% [3] - Other revenues totaled $9.1 million, marking a 25.9% increase year over year [3] Margin Analysis - Gross profit increased by 23.5% year over year to $152.1 million, with a gross margin expansion of 30 basis points to 90.3% [4][8] - Operating profit was $63.7 million, a 19.8% increase from the prior year, although the operating margin contracted by 100 basis points to 37.8% [5][8] Financial Position - Doximity ended Q2 fiscal 2026 with cash and cash equivalents of $169.2 million, up from $137.3 million at the end of Q1 [6] - Cumulative net cash from operating activities was $156 million, compared to $109.6 million a year ago [6] Future Guidance - For Q3 fiscal 2026, Doximity expects revenues between $180 million and $181 million, exceeding the Zacks Consensus Estimate of $178.2 million [7] - The full fiscal year revenue outlook has been raised to between $640 million and $646 million, up from the previous estimate of $628 million to $636 million [9] Product and Engagement Highlights - The company introduced multiple product updates focused on AI and workflow expansion, including the integration of Pathway's medical dataset into DoxGPT [11] - Record engagement was noted with over 650,000 unique prescribers utilizing various digital tools, and AI-optimized program adoption accounted for 40% of bookings [12]

Core Insights - Hims & Hers Health, Inc. (HIMS) has developed a subscription-based health and wellness platform that emphasizes personalized care, convenience, and affordability, offering treatment plans for various conditions through a digital platform [1][2] Business Model and Expansion - The company is expanding its scalable model globally, with a planned entry into Canada to offer lower-cost weight loss programs, supported by the anticipated availability of generic semaglutide [2] - The acquisition of ZAVA, a European telehealth provider, enhances Hims & Hers' reach in the U.K., Germany, France, and Ireland, strengthening its subscription-based ecosystem [2] Financial Strategy and Growth - Hims & Hers completed an $870 million convertible notes offering to accelerate growth and advance AI-driven personalization and diagnostics, reinforcing its technology-enabled care network [3] - The company has a vertically integrated infrastructure, including in-house pharmacies, which supports efficient and profitable delivery of individualized treatments [3] Market Performance - Hims & Hers shares have increased by 71.7% year-to-date, outperforming the industry growth of 20% [6] - The forward 12-month price-to-sales ratio for HIMS is 3.4X, lower than the industry average of 5.6X but higher than its three-year median of 2.5X [8] Earnings Estimates - The Zacks Consensus Estimate for HIMS' 2025 earnings per share indicates an 81.5% improvement from 2024 [9] - Current estimates for the upcoming quarters suggest a gradual increase in earnings per share, with a notable year-over-year growth forecast of 81.48% for 2025 [10]

Key Takeaways Akamai's Q3 revenues rose 5% year over year to $1.05B, topping the Zacks Consensus Estimate.Growth was led by Security Technology Group, with Guardicore and API security driving demand.For Q4, Akamai expects revenue between $1.065B-$1.085B and non-GAAP EPS of $1.65 to $1.85.Akamai Technologies Inc. (AKAM) reported strong third-quarter 2025 results, with both the top and bottom lines surpassing the Zacks Consensus Estimate.The company reported a top-line expansion year over year, driven by heal ...